The Innate Repair Receptor and the Origin of ARA-290
ARA-290, also called cibinetide in the research literature, emerged from attempts to separate erythropoietin-related tissue-protection research from erythropoietic activity. Its origin is an engineered peptide programme, not simple extraction of the complete erythropoietin molecule.
Start with the earlier receptor work
Brines and colleagues' 2004 work examined erythropoietin-related tissue protection and the common beta receptor subunit using biochemical and knockout experiments. The tested EPO/CEPO systems should not be retrospectively relabelled as experiments on ARA-290. [1]
Then identify the designed peptide
The 2008 study developed an 11-residue peptide based on the surface representation of erythropoietin's helix B region. The work distinguishes helix-B peptide constructs, the pyroglutamate helix-B surface peptide and full EPO. Its preclinical findings belong to the specific construct tested. [2]
The phrase “innate repair receptor” describes the research model used in this programme. It does not, by itself, establish that every downstream effect is caused through a fully resolved receptor interaction in every tissue.
Later endpoints require their own reading
A 2017 cibinetide trial measured corneal nerve-fibre area and other outcomes. Only the middle tested group met the primary significance comparison, while the pain comparison reported p=0.157. A structural nerve measurement and a statistically supported symptom improvement are different conclusions. [3]
| Research stage | Keep visible |
|---|---|
| Receptor-model experiments | Ligand, receptor components and model |
| Peptide design | Sequence, terminal chemistry and construct |
| Preclinical outcome | Species, comparator and measured endpoint |
| Human investigation | Primary outcome, comparison and limitations |
Connect the literature to identity carefully
The ARA-290 profile addresses the alias and specification record. A paper using cibinetide does not verify the identity, quantity or activity of a supplier lot. This lineage provides scientific context without assigning a therapeutic indication or a personal-use regimen.
Explore the related evidence
| Resource | Why open it |
|---|---|
| Receptor-Targeted Research Peptides | Browse receptor-related materials with variant limits visible. |
| ARA-290 10 mg | Open the product record for its nominal presentation and current purchasing information. |
| Receptor Agonists and Selectivity | Read binding, potency, efficacy and selectivity in context. |
| Compound Index | Find another molecular profile without confusing it with a vial. |
| Guides & Resources | Choose another scientific, analytical or procurement guide. |
Sources and scope
- Brines et al. (2004). EPO and common β-subunit receptor experiments. PNAS.EPO/CEPO biochemical association and knockout experiments, not later ARA-290 or this lot. Access: Original abstract plus primary article receptor context opened
- Brines et al. (2008). Helix-B-derived nonerythropoietic peptides. PNAS.11-residue surface design; pHBSP, HBP and full EPO kept distinct. No dose or administration instructions copied. Access: Original abstract plus accessible full original article
- Culver et al. (2017). Cibinetide, nerve measurements and pain endpoints. IOVS.Only middle dose meets primary significance; pain comparison p=0.157 not significant; surrogate versus symptoms separated. Access: Original article abstract retrieved through official Europe PMC core record